Dashboard
Manage Tickers

CYBNCYBIN INC.

NYSE cybin.com


$ 0.26 $ 0.00 (-0.47 %)    

Friday, 30-Aug-2024 15:59:42 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 0.255
$ 0.26 x 2,600
-- x --
-- - --
$ 0.23 - $ 0.74
6,510,244
na
193.81M
$ 0.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Cybi...
08/23/2024 11:31:22

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

cybin-completes-fda-type-b-initial-breakthrough-therapy-meeting-plans-for-cyb003-phase-3-program-in-major-depressive-disorder-expects-to-initiate-phase-3-in-late-summer
Cybin Completes FDA Type B Initial Breakth...
08/13/2024 11:40:17

cybin-continues-to-expect-to-commence-phase-3-pivotal-program-in-late-summer-it-had-type-b-initial-breakthrough-therapy-meeting-with-fda-late-last-week
Cybin Continues To Expect To Commence Phas...
08/13/2024 11:37:25

Doug Drysdale, Chief Executive Officer of Cybin, said, "Having selected 30 clinical sites across the United States and Euro...

cybin-q1-net-loss-c15m-same-as-last-year-cash-totaled-c183m-as-of-june-30-2024
Cybin Q1 Net Loss C$15M Same As Last Year;...
08/08/2024 12:16:33

cantor-fitzgerald-reiterates-overweight-on-cybin
Cantor Fitzgerald Reiterates Overweight on...
07/31/2024 15:38:15

Cantor Fitzgerald analyst Charles Duncan reiterates Cybin (AMEX:CYBN) with a Overweight.

hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Cybi...
07/31/2024 12:05:45

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

Core News & Articles
'MDMA Therapy Gets Support From Prominent ...
07/16/2024 18:51:34

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...

biopharma-co-cybin-reports-78m-loss-amid-accelerating-expansion-in-psychedelic-therapies-drug-development
Biopharma Co. Cybin Reports $78M Loss Amid...
06/26/2024 16:14:23

Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now!

cybin-q4-net-loss-c21m-vs-c14m-yoy-cash-totaled-c209-million-as-of-march-31-2024
Cybin Q4 Net Loss C$21M Vs. C$14M YoY, Cas...
06/26/2024 11:45:24

cantor-fitzgerald-reiterates-overweight-on-cybin
Cantor Fitzgerald Reiterates Overweight on...
06/21/2024 16:28:46

Cantor Fitzgerald analyst Charles Duncan reiterates Cybin (AMEX:CYBN) with a Overweight.

latest-executive-cannabis-changes-you-should-know-about-curaleaf-planet-13-elect-directors-and-more
Latest Executive Cannabis Changes You Shou...
06/18/2024 04:48:24

As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through...

Core News & Articles
'Oregon's First-In-Nation Psilocybin Indus...
06/12/2024 18:07:09

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment
Psychedelic Stocks Trip Up After FDA Advis...
06/05/2024 19:26:42

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...

hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Cybi...
05/16/2024 17:09:07

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

pot-company-gets-license-to-open-psilocybin-service-center-the-sacred-mushroom-in-oregon
Pot Company Gets License To Open Psilocybi...
05/09/2024 13:29:42

Core News & Articles
"FDA Expert Committee Will Review MDMA-Ass...
05/07/2024 15:54:11

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

cybin-provides-corporate-update-and-highlights-upcoming-clinical-milestones-initiation-of-pivotal-cyb003-phase-3-study-in-mdd-expected-in-mid-2024-phase-2-topline-efficacy-and-safety-results-for-cyb004-in-generalized-anxiety-disorder-expected-q4-2024
Cybin Provides Corporate Update And Highli...
05/06/2024 12:42:05

- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports adva...

cybin-announces-grant-of-additional-us-patent-in-support-of-its-cyb003-breakthrough-therapy-program-for-major-depressive-disorder
Cybin Announces Grant Of Additional US Pat...
04/16/2024 11:35:02

psychedelics-headlines-a-form-of-life-treating-chronic-pain-microdosing-and-more
Psychedelics Headlines: A Form Of Life, Tr...
03/30/2024 12:57:44

psyched-lsd-psilocybin-as-breakthrough-therapies-14m-fed-grant-for-ibogaine-indianas-research-and-more
Psyched: LSD, Psilocybin As Breakthrough T...
03/20/2024 18:49:36

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION